West Pharmaceutical Services (WST) Current Assets (2009 - 2026)

West Pharmaceutical Services (WST) has reported Current Assets for 18 consecutive years, with $1.8 billion the latest figure, recorded in Q2 2026.

• Quarterly Current Assets rose 7.53% year-over-year to $1.8 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.8 billion (up 7.53% YoY) and the FY2025 annual result came in at $2.0 billion, up 28.61% from the prior year.
• Current Assets eased to $1.8 billion in Q2 2026 per WST's latest filing, from $1.8 billion in the prior quarter.
• Over the last five years, Current Assets for WST reached as high as $2.0 billion in Q4 2025 and fell as low as $1.5 billion in Q1 2025.
• A 5-year average of $1.8 billion and a median of $1.8 billion in 2022 frame the typical range for Current Assets.
• Annual changes were most pronounced in 2024 — Current Assets retreated 21.38% — and 2025, when it increased 28.61%.
• Year by year, Current Assets stood at $1.9 billion in 2022, then rose by 0.88% to $1.9 billion in 2023, then dropped by 20.57% to $1.5 billion in 2024, then grew by 28.61% to $2.0 billion in 2025, then retreated by 8.63% to $1.8 billion in 2026.
• According to Business Quant data, Current Assets over the past three periods registered $1.8 billion, $1.8 billion, and $2.0 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.